首页> 美国卫生研究院文献>Journal of Hematology Oncology >Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms
【2h】

Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms

机译:巯氧吡啶镍通过Bcr / Abl依赖性和Bcr / Abl依赖性机制诱导对伊马替尼耐药的慢性粒细胞白血病细胞凋亡

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundAcquired imatinib (IM) resistance is frequently characterized by Bcr-Abl mutations that affect IM binding and kinase inhibition in patients with chronic myelogenous leukemia (CML). Bcr-Abl-T315I mutation is the predominant mechanism of the acquired resistance to IM. Therefore, it is urgent to search for additional approaches and targeting strategies to overcome IM resistance. We recently reported that nickel pyrithione (NiPT) potently inhibits the ubiquitin proteasome system via targeting the 19S proteasome-associated deubiquitinases (UCHL5 and USP14), without effecting on the 20S proteasome. In this present study, we investigated the effect of NiPT, a novel proteasomal deubiquitinase inhibitor, on cell survival or apoptosis in CML cells bearing Bcr-Abl-T315I or wild-type Bcr-Abl.
机译:背景技术获得性伊马替尼(IM)耐药性通常以Bcr-Abl突变为特征,这些突变会影响慢性粒细胞性白血病(CML)患者的IM结合和激酶抑制。 Bcr-Abl-T315I突变是获得性抗IM的主要机制。因此,迫切需要寻找其他方法和目标策略来克服IM抵抗。我们最近报道,巯氧吡啶氧化镍(NiPT)通过靶向19S蛋白酶体相关的去泛素酶(UCHL5和USP14),有效抑制泛素蛋白酶体系统,而不影响20S蛋白酶体。在本研究中,我们研究了新型蛋白酶体去泛素酶抑制剂NiPT对带有Bcr-Abl-T315I或野生型Bcr-Abl的CML细胞的细胞存活或凋亡的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号